A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID)
- 30 November 2011
- journal article
- Published by Elsevier BV in Molecular Genetics and Metabolism
- Vol. 104 (3), 383-389
- https://doi.org/10.1016/j.ymgme.2011.07.007
Abstract
No abstract availableKeywords
Funding Information
- NHGRI, NIH, Division of Intramural Research (NO1-AI-30070)
- Jeffrey Modell Foundation
This publication has 36 references indexed in Scilit:
- Guidelines for implementation of population‐based newborn screening for severe combined immunodeficiencyJournal of Inherited Metabolic Disease, 2010
- Systematic Evidence Review of Newborn Screening and Treatment of Severe Combined ImmunodeficiencyPEDIATRICS, 2010
- Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimerasBlood, 2009
- Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: Current status and critical needsJournal of Allergy and Clinical Immunology, 2008
- From Public Health Emergency to Public Health Service: The Implications of Evolving Criteria for Newborn Screening PanelsPEDIATRICS, 2006
- Potential Costs and Benefits of Newborn Screening for Severe Combined ImmunodeficiencyThe Journal of Pediatrics, 2005
- Quality of Life of Children with Cystic FibrosisThe Journal of Pediatrics, 2005
- Parental attitudes regarding newborn screening of PKU and DMDAmerican Journal of Medical Genetics Part A, 2003
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- Neonatal screening for sickle cell disease: A cost-effectiveness analysisThe Journal of Pediatrics, 1991